Catalyst Final Award
Principal Investigator: Chelsea Bahney, PhD
Team Members: Ralph Marcucio, PhD – Ted Miclau, MD
Interns: Tracy Knight, PhD candidate – Olivia Barnhill, PhD candidate
Project Name: Nexocura – Next Generation Fracture Healing
"The first locally delivered RNA nanotherapeutic that stimulates fracture healing without additional surgery."
Catalyst Final Award
Principal Investigators: Zachary Gale-Day, PhD – Jason Gestwicki, PhD
Team Members: Douglas Gould, PhD – Yoshihiro Ishikawa, PhD
Intern: Lin Xu, MTM candidate
Project Name: Reciprocal Therapeutics – Protein Replacement for Alport Syndrome
Engineering the next generation of treatments for Alport Syndrome.
Weill Institute-Catalyst Final Award
Principal Investigator: Su Guo, PhD
Team Members: Priya Jaishankar, MS – Mathieu Daynac, PhD – Chad Christine, MD
Interns: Santhosh Arul, PhD – Can Wang, PhD
Project Name: AngioMind BioSciences – Neuroprotection in a Pill From Day One for Parkinson's Disease
"An oral, BBB-penetrant, disease-modifying treatment for early-stage Parkinson’s disease (PD), diagnosed with the alpha-synuclein seed amplification assay."
Weill Institute-Catalyst Final Award
Co-Principal Investigators: Hideho Okada, MD, PhD – Joseph Costello, PhD – Darwin Kwok, PhD – Nick Stevers, PhD
Interns: Charlotte Wang, PhD candidate – Lyra Li
Project Name: Omneo Therapeutics – Advancing a First-in-Class Immunotherapy Targeting a Tumor-wide Splicing-Derived Neoantigen for Solid Tumors
"Omneo Therapeutics is developing OMN-001, a first-in-class, off-the-shelf vaccine targeting universal splicing-derived neoantigens to eliminate tumor heterogeneity and prevent recurrence in glioblastoma."
Principal Investigator: Adam Renslo, PhD - Daniel Minor, Jr., PhD
Team Members: Tyson Kim, MD, PhD
Interns: Beatrice Mihalache, PhD candidate – Chae Joon Lee, PharmD candidate
Project Name: TREK-1 Agonists with Sustained Intraocular pressure-Lowering Effects in Glaucoma
"We are developing the first long-acting topical treatment for glaucoma patients seeking improved IOP control in a convenient, once-weekly drop that preserves vision and the health of the ocular surface."
Catalyst Final Award – Co-Funded wth School of Pharmacy
Principal Investigator: Pamela M. England, PhD
Team Members: Phuong Nguyen, PhD
Intern: Simeiyun (May) Liu, PhD
Project Name: PNRx Bio – Developing a PNR-targeting Molecule for a Mutation-agnostic treatment of RHO-associated retinal degeneration
"Our solution is a once-a-day pill that inhibits PNR to reduce the expression of rhodopsin."
